Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Shares Issued (2016 - 2025)

Vistagen Therapeutics' Shares Issued history spans 11 years, with the latest figure at $30.5 million for Q4 2025.

  • For Q4 2025, Shares Issued rose 34732.95% year-over-year to $30.5 million; the TTM value through Dec 2025 reached $30.6 million, down 67.21%, while the annual FY2024 figure was $93.5 million, N/A changed from the prior year.
  • Shares Issued for Q4 2025 was $30.5 million at Vistagen Therapeutics, up from -$236000.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $93.4 million in Q1 2024 and bottomed at -$36.0 million in Q4 2023.
  • The 4-year median for Shares Issued is $774442.0 (2023), against an average of $12.9 million.
  • The largest YoY upside for Shares Issued was 34732.95% in 2025 against a maximum downside of 368.18% in 2025.
  • A 4-year view of Shares Issued shows it stood at $4.9 million in 2021, then crashed by 835.22% to -$36.0 million in 2023, then soared by 99.76% to -$88000.0 in 2024, then surged by 34732.95% to $30.5 million in 2025.
  • Per Business Quant, the three most recent readings for VTGN's Shares Issued are $30.5 million (Q4 2025), -$236000.0 (Q3 2025), and $397000.0 (Q2 2025).